Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response

Posted: 2021-11-05 19:00:00
Background: SARS-CoV-2 vaccines are an invaluable resource against COVID-19. Current vaccine shortage makes it necessary to prioritize distribution to the most appropriate segments of the population. Methods: This is a prospective cohort study of 63 health care workers (HCWs) from a General Hospital. We compared antibody responses to two doses of BNT162b2 mRNA COVID-19 vaccine between HCWs with previous SARS-CoV-2 infection (experienced HCWs) and HCWs without previous infection (naïve HCWs). Findings: Seven days after the first vaccine dose, HCWs with previous infection experienced a 126-fold increase in antibody levels (p<0·001). However, in the HCW naïve group, response was much lower and only five showed positive antibody levels (>50 AU). After the second dose, no significant increase in antibody levels was found in experienced HCWs, whereas in naïve HCWs, levels increased by 16-fold (p<0·001). Approximately two months post-vaccination, antibody levels were much lower in naïve HCWs compared to experienced HCWs (p<0·001). Interpretation: The study shows that at least ten months post-COVID-19 infection, the immune system is still capable of producing a rapid and powerful secondary antibody response following one single vaccine dose. Additionally, we found no further improvement in antibody response to the second dose in COVID-19 experienced HCWs. Nonetheless, two months later, antibody levels were still higher for experienced HCWs. These data suggest that immune memory persists in recovered individuals; therefore, the second dose of the COVID-19 vaccine in this group could be postponed until immunization of the remaining population is complete. Keywords: Immune memory; Previous SARS-CoV-2 infection; SARS-CoV-2 vaccines; Secondary antibody response.

参考サイト PubMed: covid-19


2月 10, 2021 バイオアソシエイツ


シカゴにあるラッシュ大学医療センターの新研究で、マウスの COVID-19 モデルに鼻からペプチドを導入したところ、効果を示したという。 このペプチドは、発熱を抑え、肺を保護し、心臓機能を改善し、「サイトカインストーム」(感染が免疫系を誘発して炎症性タンパク質で血流を溢れさせる状態)を逆転させるのに効果的であることが証明された。この研究者らはまた、病気の進行を防ぐことに成功したと報告している。2021年1月11日にJournal of Neuroimmune…

ゲスト 841人 と メンバー 4人 がオンラインです